Selective α7 nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processes
Graphical abstract
α7 Neuronal nicotinic receptor activation of midbrain dopamine neurons improves selective attention and acquisition of operant and object recognition behaviors.
Introduction
Nicotine and selective NNR agonists activate central neuronal nicotinic receptors and have been shown to enhance memory and attention. Activation of NNRs has been shown to modulate neurotransmitter release and function throughout the central nervous system, specifically this cognition enhancement is thought to be, at least in part, mediated through modulation of dopaminergic and glutamatergic transmission [1]. NNR subtypes composed of pentameric arrangements of α2, α4, α6, β2, and β4 subunits as well as α7 subunits show distinct neuro-anatomical distributions in mammalian brain consistent with involvement in the modulation of excitatory and inhibitory synaptic networks. Particularly, these subtypes of NNRs are expressed in the mesostriatal and mesolimbic dopamine pathways and have been shown to modulate the firing patterns of these dopaminergic neurons [2], [3], [4], [5]. Appropriate activation of midbrain dopaminergic neurons is crucial to many of the motivational aspects of goal directed behavior and decision-making. These aspects of behavior include the allocation of attentional resources and processes involved in reward evaluation, prediction, and outcome expectancy. In both human and animal models, the functional properties of the dopamine system influence an organism's ability to alter behavioral choices based upon recent experience and have been shown to correlate with improvements in learning and memory [3], [21]. While dopaminergic dysfunction is implicated in the motivational and cognitive abnormalities associated with a number of neurological and psychiatric disorders, neuronal mechanisms regulating dopaminergic function in vivo are not well established.
Despite an incomplete understanding of dopamine's regulation in vivo, converging molecular, pharmacological, and physiological evidence indicates a role for cholinergic inputs in the regulation of the midbrain dopaminergic system. Of particular importance in the control of dopamine release is a diverse set of nicotinic receptors located both directly on dopamine-producing cells within the ventral tegmental area (VTA) as well as on local inhibitory interneurons. Nicotine directly activates VTA neurons causing a number of time-dependent changes in dopamine release. Dopamine system activation is thought to account for the rewarding properties of nicotine and may also partially account for nicotine-associated improvements in attention and memory [3]. Nevertheless, the functional roles played by distinct subtypes of nicotinic receptors relative to the dopamine system remain to be fully elucidated.
Here we show that administration of low doses of a selective α7 NNR agonist, AZD0328, leads to a significant increase in the excitability of midbrain dopaminergic neurons with no independent change in the spike patterns produced by these neurons. Within the same dose range, AZD0328 led to a significant increase in cortical dopamine release in awake rodents and improved both conditioned response learning and memory retention in an object recognition task. The selective α7-receptor antagonist, methyllycaconitine (MLA), blocked the dopamine releasing and memory improving functions of AZD0328. Interestingly, during the training phase of the object recognition test, AZD0328 administration led to a robust increase in the targeted and selective exploration of objects without an overall increase in locomotor activity. To confirm the primary receptor requirement for AZD0328's mechanism of action, we tested the effect of AZD0328 on novel object recognition (NOR) in Chrna7 knockout mice and their non-transgenic littermates. This novel finding suggests a role for α7 NNRs in the selective allocation of attentional resources mediated, in part, by an enhancement in dopamine release. Together, these data provide mechanistic insight into how highly selective α7 agonists can be used to treat attentional and motivational abnormalities associated with a number of neurological and psychiatric conditions including: Alzheimer's disease, schizophrenia, bipolar disorder and attention deficit hyperactivity disorder (ADHD).
Section snippets
Test compounds
AZD0328 ((2′R)-spiro-[1-azabicyclo[2.2.2]octane-3,2′(3′H)-furo[2,3-b]pyridine] d-tartrate) (structure shown in Fig. 1) was prepared by AstraZeneca Wilmington CNS Discovery Chemistry [6]. For in vitro studies, AZD0328 was dissolved in distilled water or DMSO before use. For in vivo studies, AZD0328 was dissolved in 0.9% saline or phosphate buffered saline before use. Chloral hydrate, ketamine, methyllycaconitine, xylazine and all other reagents were purchased from Sigma–Aldrich (St. Louis, MO).
Receptor binding
Results
The in vitro binding characteristics of AZD0328 were determined on nicotinic receptor subtypes, and the structurally related 5HT3 receptor, using a wide variety of radioligands and membrane preparations (Table 1). AZD0328 exhibited high affinity for the native α7 NNR of rat hippocampal membranes using the classical α7 antagonist radioligand [125I]α-bungarotoxin. AZD0328 exhibited similar high affinity for the human α7 NNR stably expressed in HEK-293 cell membranes as assessed with [125I]α-BTX
Discussion
Numerous α7 NNR agonists have been reported in the literature [19] and a few have now begun to yield clinical data in early trials with normal subjects, Alzheimer's and schizophrenia patients [20]. AZD0328 is unique in that its exceptional drug-like properties allow the attainment of efficacious brain exposure with low doses in animal models (Table 5). The consistency of these low dose effects across multiple preclinical models has permitted us to efficiently translate effects on dopamine
References (32)
- et al.
In vivo activation of midbrain dopamine neurons via sensitized, high-affinity alpha 6 nicotinic acetylcholine receptors
Neuron
(2008) - et al.
5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective α7 nicotinic receptor partial agonist
Bioorg Med Chem Lett
(2001) - et al.
Hierarchical control of dopamine neuron-firing patterns by nicotinic receptors
Neuron
(2006) - et al.
Effects of delayed reinforcers on the behavior of an animal model of attention-deficit/hyperactivity disorder (ADHD)
Behav Brain Res
(2005) - et al.
Acquisition, extinction, and reacquisition of responding with delayed and immediate reinforcement
Behav Process
(1998) - et al.
The effects of acute and repeated pyridostigmine bromide administration on response acquisition with immediate and delayed reinforcement
Pharmacol Biochem Behav
(1999) - et al.
Disruption of acquisition and performance of operant response-duration differentiation by unilateral nigrostriatal lesions
Behav Brain Res
(2000) - et al.
α7 nicotinic acetylcholine receptor agonists and positive allosteric modulators
Prog Med Chem
(2008) - et al.
Dopamine scales performance in the absence of new learning
Neuron
(2006) - et al.
Regional and temporal differences in real-time dopamine efflux in the nucleus accumbens during free-choice novelty
Brain Res
(1997)
The computational neurobiology of learning and reward
Curr Opin Neurobiol
Temporal and probabilistic discounting of reward in children and adolescents: effects of age and ADHD symptoms
Neuropsychologia
Response acquisition with delayed reinforcement in a rodent model of attentio-deficit/hyperactivity disorder (ADHD)
Behav Brain Res
A new one trial test for neurobiological studies of memory in rats, 1. behavioral data
Behav Brain Res
Further concerns over Cheng–Prusoff analysis trends
Pharm Sci
Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system
Annu Rev Pharmacol Toxicol
Cited by (91)
Nicotinic acetylcholine receptors: Key targets for attenuating neurodegenerative diseases
2023, International Journal of Biochemistry and Cell BiologyThe human-specific duplicated α7 gene inhibits the ancestral α7, negatively regulating nicotinic acetylcholine receptor-mediated transmitter release
2021, Journal of Biological ChemistryNicotinic Receptor Ligands and Novel Object Recognition
2018, Handbook of Behavioral NeuroscienceCitation Excerpt :Preclinical studies with α7 nAChR agonists (e.g., ABT-107, GTS-21, EVP-6124, RG-3487, SSR-180,711 and TC-5619) have demonstrated robust procognitive effects across multiple cognitive domains (attention, spatial reference memory, working memory and executive function) in experimental animals (Arendash et al., 1995; Bitner et al., 2010; Callahan et al., 2017; Hauser et al., 2009; Levin et al., 1999; Prickaerts et al., 2012; Wallace et al., 2011), including object recognition memory (see Table 26.1). As a drug class, α7 nAChR agonists have shown consistent effects in their ability to produce ‘stand-alone’ procognitive effects on object recognition in rodents (Callahan et al., 2014, 2017; Pichat et al., 2007; Prickaerts et al., 2012; Roncarati et al., 2009; Sydserff et al., 2009) and these procognitive effects have been maintained following chronic administration indicating a lack of tolerance to repeated drug administration (Pichat et al., 2007; Wallace et al., 2011; Van Goethem et al., 2015). Moreover, α7 nAChR agonists are capable of influencing all stages of recognition memory (i.e., acquisition, consolidation and retrieval; Callahan et al., 2017; Prickaerts et al., 2012; McLean et al., 2016; Wallace et al., 2011).
Design and synthesis of a novel series of (1′S,2R,4′S)-3H-4′-azaspiro[benzo[4,5]imidazo[2,1-b]oxazole-2,2′-bicyclo[2.2.2]octanes] with high affinity for the α7 neuronal nicotinic receptor
2017, Bioorganic and Medicinal Chemistry LettersThe current agonists and positive allosteric modulators of α7 nAChR for CNS indications in clinical trials
2017, Acta Pharmaceutica Sinica B